Plague
Recent clinical, regulatory, research and industry developments relating to this disease.
Plague: past, present, and future.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q1 2027.
- 2 industry developments reported.
- Q1 2027Phase 2, Randomized, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
- Q2 2027Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Dose Expansion Study to Assess the Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody, JST-010, in Healthy Adults
Clinical MilestonesViewHide
- 2026-06-18Phase 2, Randomized, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of AgeResults expected Q1 2027
- 2026-05-12Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Dose Expansion Study to Assess the Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody, JST-010, in Healthy AdultsResults expected Q2 2027
Industry & MarketViewHide
- 2026-06-17DNA from hunter-gatherer teeth reveals secrets of ancient plagueIndustry · Nature News
- 2026-06-17Lethal plague outbreaks in Lake Baikal hunter-gatherers 5,500 years agoIndustry · Nature News
- 2026-06-18ClinicalPhase 2, Randomized, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of AgeResults expected Q1 2027
- 2026-06-17IndustryDNA from hunter-gatherer teeth reveals secrets of ancient plagueIndustry · Nature News
- 2026-06-17IndustryLethal plague outbreaks in Lake Baikal hunter-gatherers 5,500 years agoIndustry · Nature News
- 2026-06-03ClinicalA Randomized, Non-inferiority, Active Controlled Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin Versus Doxycycline in the Treatment of Plague in HumansResults posted
- 2026-05-12ClinicalPhase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Dose Expansion Study to Assess the Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody, JST-010, in Healthy AdultsResults expected Q2 2027
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- PLoS medicine1
Leading researchers8
- Atshabar BB1
- Begon M1
- Belmain SR1
- Bertherat E1
- Carniel E1
- Gage KL1
- Leirs H1
- Rahalison L1
Affiliations (unnormalised)1
- Centre for Ecological and Evolutionary Synthesis1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.